India-based pharmaceutical company Dr Reddy’s Laboratories has partnered with the Russian Direct Investment Fund (RDIF) for clinical trials and supply of Sputnik V Covid-19 vaccine.
After obtaining regulatory approval in India, RDIF will supply 100 million doses of the vaccine to Dr Reddy’s for distribution in the country.
Deliveries should start in the coming months, subject to completion of trials and regulatory registration of the vaccine in India.
Based on human adenoviral vector platform, Sputnik V is currently in clinical trials, developed by the Gamaleya National Research Institute of Epidemiology and Microbiology in Russia.
Russian Direct Investment Fund CEO Kirill Dmitriev said: “India is amongst most severely impacted countries from Covid-19 and we believe our human adenovirus dual vector platform will provide a safe and scientifically validated option to India in the battle against Covid-19.
“The platform of human adenoviral vectors, which is the core of the Russian vaccine, has been tested in more than 250 clinical studies over decades, and it has been found safe with no potential negative long-term consequences.”
On 11 August, the Ministry of Health of Russia registered Sputnik V, marking the world’s first registered Covid-19 vaccine based on the human adenoviral vectors platform.
Dr. Reddy’s Laboratories co-chairman and managing director G V Prasad said: “The Phase I and II results have shown promise, and we will be conducting Phase-III trials in India to meet the requirements of the Indian regulators. Sputnik V vaccine could provide a credible option in our fight against Covid-19 in India.”
Last month, RDIF and the Brazilian state of Parana announced a collaboration to produce and distribute Sputnik V.